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To uncover the potential cardiovascular effects of human polymor-
phisms influencing transforming growth factor β1 (TGFβ1) expres-
sion,wegeneratedmicewith Tgfb1mRNAexpression graded infive
steps from 10% to 300% normal. Adrenal expression of the genes
for mineralocorticoid-producing enzymes ranged from 50% normal
in the hypermorphs at age 12 wk to 400% normal in the hypo-
morphs accompanied with proportionate changes in plasma aldo-
sterone levels, whereas plasma volumes ranged from 50% to 150%
normal accompanied by marked compensatory changes in plasma
angiotensin II and renin levels. The aldosterone/renin ratio ranged
from 0.3 times normal in the 300% hypermorphs to six times in the
10%hypomorphs,which have elevated bloodpressure. Urinary out-
put of water and electrolytes are markedly decreased in the 10%
hypomorphs without significant change in the glomerular filtration
rate. Renal activities for the Na+, K+-ATPase, and epithelial sodium
channel aremarkedly increased in the 10%hypomorphs. The hyper-
tension in the 10% hypomorphs is corrected by spironolactone or
amiloride at doses that do not change blood pressure in wild-type
mice. Thus, changes in Tgfb1 expression cause marked progressive
changes in multiple systems that regulate blood pressure and fluid
homeostasis, with the major effects being mediated by changes in
adrenocortical function.
idiopathic bilateral adrenal hyperplasia | hyperthermia
Transforming growth factor β1 (TGFβ1), the prototypic memberof the TGFβ superfamily, is a potent multifunctional cytokine
with effects on a broad range of biological processes including cell
proliferation, apoptosis, tumor suppression, senescence (1, 2), dif-
ferentiation (3), migration (4), immunity (5), osteogenesis (6),
adipogenesis (7), and wound healing (8).
Whether TGFβ1 plays any role in the control of blood pressure
(BP) is not yet clearly demonstrated. Mice have been generated
that completely lack TGFβ1 (9, 10), but their death from severe
inflammatory disease around weaning precludes BP measure-
ments. The inflammatory disease and early death can be circum-
vented if the mice also lack functional T and B cells as a result of
inactivating the recombination activating gene, Rag1 (11). Un-
fortunately, inactivating Rag1, either alone or in conjunction with
inactive Tgfb1, disturbs the systems controlling BP (12). In humans,
the 915C allele of a single nucleotide polymorphism in TGFB1,
which leads to proline at residue 25 within the signal peptide se-
quence, has been associated in a European population with a re-
duced risk of hypertension (13). The 897C allele of a second
polymorphism, which leads to proline at residue 10within the signal
peptide sequence, has been associated in an Asian population with
an increased risk of hypertension (14, 15), but whether or how the
changes directly affect BP has not been determined.
These studies document the complex effects on the cardiovas-
culature that result from changes in TGFβ1 function. However, no
clear picture emerges of the effects of inherited variations that
simply change the basal level of TGFβ1 expression without alter-
ing the amino acid sequences of the polypeptides that result.
This type of information is of particular importance when amino
acid sequences are as highly conserved as are those of the TGFβ1
polypeptides. Thus, 111 of the 112 residues that comprise the
TGFβ1 active product are identical in the mouse and human, and
large stretches in the remaining 278 residues of the TGFβ1 pre-
cursor are also identical (16).
Accordingly, we have generated mice having Tgfb1 expression
∼10%, 50%, 200%, and 300% normal, which covers the range
likely in the general human population. We find that multiple
parameters known to regulate BP or respond to changes in it are
affected in a remarkably proportionatemanner by these changes in
Tgfb1 expression, indicating that even modest inherited changes in
the expression of the human TGFB1 gene are likely to have sig-
nificant cardiovascular effects.
Results
Generation of Hypo/Hypermorphic Mice for TGFβ1. As a preliminary
to using gene targeting to generate mice expressing altered levels
of TGFβ1, we first used our published system (17) to compare the
relative effects on mRNA stability of the 3′-untranslated region
(UTR) ofTgfb1 compared with a panel of other 3′-UTRs. This test
indicated that we could obtain informatively low and high levels of
TGFβ1 expression by using gene targeting to replace the natural
3′-UTR of the Tgfb1 with the unstable 3′-UTR of the FBJ osteo-
sarcoma oncogene (Fos) or with the stable 3′-UTR from the
bovine growth hormone gene (bGH) (Fig. S1 A–C).
To obtain the desired mice, we used a targeting procedure (17),
which initially generates a form of the Tgfb1 gene (Tgfb1L) that
gives low expression because it produces an unstable mRNA
having the 3′-UTR from Fos (Fig. 1 A, lines A–C, and B); after ex-
posure to Cre recombinase, the low-expressing allele is converted
into a high-expressing form (Tgfb1H) because it produces a very
stable mRNA having the 3′-UTR from bGH (Fig. 1 A, line D).
Targeting was with C57BL/6-derived embryonic stem cells, and
the resulting Tgfb1L/+ mice were maintained as C57BL/6 inbreds.
Tgfb1L/+ mice were mated with inbred C57BL/6 mice carrying
a ubiquitously expressed Cre recombinase to generate Tgfb1H/+
mice. Subsequent matings of mice carrying the low and high
expressing alleles, yielded mice with the following five genotypes:
Tgfb1L/L (L/L),Tgfb1L/+ (L/+),Tgfb1+/+ (WT),Tgfb1H/+ (H/+), and
Tgfb1H/H (H/H) mice. These mice express graded levels of Tgfb1
mRNA relative to their wild-type (WT) littermates in all six
tissues tested (Fig. 1B). A two-way ANOVA test showed that the
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differences in relative Tgfb1 expression due to genotype (P < 10−4)
were not affected by tissue (P = 0.89), and there was no in-
teraction between genotype and tissue (P = 0.98). The averaged
values of Tgfb1mRNA expression from the six tissues relative to
WT (100%) of the five types of mice are 10± 7% for L/L, 62± 6%
for L/+, 100 ± 7% for WT 182 ± 7% for H/+, and 293 ± 7% for
H/H. The levels of active TGFβ1 protein in the plasma of mice
with the five genotypes increased in proportion to the mRNA
levels and spanned a range from ∼20% to ∼200% normal (Fig.
1C). The relative amounts of phosphorylated Smad2 (p-Smad2),
which reflects the activity of intracellular TGFβ signaling, in the
kidneys of mice of the five genotypes also increased in proportion
to the Tgfb1 mRNA levels (Fig. 1D).
We conclude that the four types of mice generated by our gene
targeting procedure have Tgfb1 mRNA expression of ∼10%,
50%, 200%, and 300% normal, which covers the range likely to
occur in the general human population.
Blood Chemistry and Hematology of the TGFβ1 Hypo/Hypermorphic
Mice. Plasma glucose, plasma insulin, plasma urea nitrogen, plasma
creatinine, plasma sodium, plasma chloride, and plasma osmo-
larity (Tables S1 and S2) were indistinguishable from WT in all of
the mice at age 12 wk except that plasma potassium of the L/L
mice was significantly less than WT (4.9 ± 0.1 mEq/L and 5.7 ±
0.1 mEq/L; P for L/L vs. WT <10−4).
Hematocrits of the L/L, L/+, H/+, and H/H mice were in-
distinguishable from WT (Tables S1 and S2).
Adrenocortical Function in the TGFβ1 Hypo/Hypermorphic Mice.
Plasma aldosterone levels increased progressively as the geneti-
cally controlled expression ofTgfb1 decreased, ranging from∼50%
belowWT in the H/H mice to ∼200% of WT in the L/L mice (Fig.
2A). Plasma corticosterone levels (Fig. 2B) were significantly
higher than normal in the L/L mice (329 ± 57 and 145± 23 ng/mL;
P for L/L vs. WT <0.01).
Adrenal mRNA expression of the two genes that determine the
mitochondrial enzymes directly involved in the synthesis of cor-
ticosterone and its product aldosterone, 11 beta hydroxylase
(Cyp11b1) and aldosterone synthase (Cyp11b2), closely matched
the progressive changes in plasma aldosterone levels (Fig. 2C).
Other genes involved in steroidogenesis, steroidogenic acute reg-
ulatory protein (Star), hydroxy-delta-5-steroid dehydrogenase, 3
beta- and steroid delta-isomerase 1 (Hsd3b1), and 21-hydroxylase
(Cyp21a1), had increased expression when Tgfb1 expression was
below normal, although only in the L/L adrenals did this reach
significance (Fig. 2C).
Microscopic examination of the adrenals showed no structural
abnormalities, such as nodular hyperplasia, in any of the mice
(Fig. S3), but the adrenal weight normalized to body weight was
doubled in the L/L mice (0.155 ± 0.014% body weight vs. 0.082 ±
0.007% body weight; P L/L vs. WT <0.05; Tables S1 and S2).
Together these data demonstrate that genetically determined
changes in Tgfb1 expression from above to below normal cause a
parallel shift in aldosterone and corticosterone production from
above to below normal, largely due to altered expression of the




Fig. 1. Generation ofmice having genetically graded expression
of TGFβ1. L/L, Tgfb1L/L; L/+, Tgfb1L/+; WT, Tgfb1+/+; H/+, Tgfb1H/+;
andH/H, Tgfb1H/H. *P< 0.05, **P< 0.01, †P< 0.001, ††P<10−4, ‡P<
10−5vs.WT. (A) Thetargetingstrategy. (A, lineA)Thetarget locus is
Tgfb1. Coding sequences and theendogenous 3′-UTRof theTgfb1
gene are shown as black and white columns. (A, line B) The tar-
getingvector containsa loxP sequence, thec-Fos3′-UTR (blue), two
copiesofa transcriptional insulator (cHS) fromthechicken β-globin
gene (yellow), a Neo gene with the MC1 promoter (pMC1), loxP,
and the 3′-UTR of the bovine growth hormone gene (bGH3′-UTR,
red). The insulators minimize interference between the Tgfb1
promoter and pMC1. TK, thymidine kinase gene. (A, line C) The
locus after homologous recombination. TGFβ1 expression is now
controlledby the3′-UTRof Fos [“low” (L) allele],whichdestabilizes
theTGFβ1mRNAanddecreasesTGFβ1protein. (A, lineD)The locus
after Cre-lox P recombination. TGFβ1 expression is controlled by
the3′-UTRofbGH [“high” (H) allele],which stabilizesTGFβ1mRNA
andincreasesTGFβ1protein.GenetargetingwasconfirmedbyPCR
with primers (F and R) and by a Southern blot (Fig. S2) with tail
genomic DNA digested by Nco I radiolabeled with a probe (P). (B)
ThemRNA levels of TGFβ1 indifferent tissues in thefivegenotypes
of 12-wk-oldmalemice. (C) Plasma concentrations of TGFβ1 in the
fivegenotypesof 12-wk-oldmalemice. (D) Phosphorylated Smad2
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Fig. 2. Adrenocortical function in the TGFβ1 hypo/hypermorphic mice at
age 12 wk. *P < 0.05, **P < 0.01, †P < 0.001, ††P < 10−4, ‡P < 10−5 vs. WT. (A)
Plasma aldosterone levels. (B) Plasma corticosterone levels. (C) The mRNA
levels for enzymes required for aldosterone synthesis in the adrenal gland.
(D) Plasma volume. BW, body weight.











Plasma Volumes of the TGFβ1 Hypo/Hypermorphic Mice. Plasma
volumes of the mice as a percentage of their body weights ranged
from ∼50% below normal in the H/H mice to ∼50% above
normal in the L/L mice (Fig. 2D). However, despite these pro-
gressive changes in plasma volumes, the plasma vasopressin con-
centrations in L/L and WT mice were not significantly different
[WT (n = 5): 7.1 ± 0.7 pg/mL vs. L/L (n = 6): 7.4 ± 1.4 pg/mL, P =
0.84]. Nor were plasma adrenocorticotropic hormone (ACTH)
[WT (n = 5): 280 ± 37 pg/mL vs. L/L (n = 5): 291 ± 39 pg/mL,
P = 0.85] or cardiac expression of atrial natriuretic peptide
different from WT [WT (n = 6): 100 ± 16% vs. Tgfb1L/L (n = 6):
64 ± 9%, P = 0.11]. These observations suggest that the most
likely factor determining the progressive changes in plasma
volume is a shift in sodium reabsorption caused by the pro-
gressive changes in plasma aldosterone levels resulting from the
genetically determined differences in Tgfb1 expression.
Blood Pressure in the Tgfb1 Hypo/Hypermorphic Mice. The L/L mice
had a markedly higher systolic blood pressure (sBP) than WT
whether studied with a tail-cuff method (138± 3mmHg vs. 106± 3
mmHg; P < 10−5) or by telemetry (146 ± 3 mmHg vs. WT 120 ± 2
mmHg; P < 10−5); the pulse rate of the L/L mice was substantially
lower thanWT by both methods (by telemetry, 494 ± 16 beats/min
vs. 661 ± 15 beats/min; P < 0.001); the sBPs and pulse rates of the
other mice were indistinguishable from WT (Fig. 3 A–D).
Graded Changes in the Renin-Angiotensin System in TGFβ1 Hypo/
Hypermorphs. Multiple changes occurred in the renin–angiotensin
system in response to the genetically controlled changes in Tgfb1
expression, all in the direction that would be expected to main-
tain normal blood pressure in the face of either abnormally low
or high blood volumes. Thus, the plasma concentration of angio-
tensin II ranged from ∼30% normal in the L/L mice to ∼200%
normal in the H/H mice in inverse correlation with the plasma
volumes (Fig. 4A). Plasma renin levels, Renin 1c (Ren1c) mRNA
levels in the kidney, Angiotensin converting enzyme (Ace)
mRNA levels in the lung, and Angiotensinogen (Agt) mRNA
levels in the liver all show similar changes, although the L/L
and H/H mice had proportionately greater responses than the
L/+ and H/+ mice (Fig. 4 B and C).
Nitric Oxide and the Other Blood Pressure-Controlling Systems in
TGFβ1 Hypomorphs. Because previous studies suggest that both
TGFβ1 and aldosterone affect the activity and/or expression of
endothelial nitric oxide (NO) synthase (eNOS) (18, 19), the hy-
pertension in the L/L mice could be due partly to a decrease in
eNOS function. To evaluate this possibility, we measured protein
content of serine1177-phosphorylated eNOS in the kidney and
found it to be greater in the L/L mice than in WT (Fig. 5A),
although threonine495-phosphorylated eNOS, total eNOS, and
eNOS mRNA levels are comparable between the two geno-
types (Fig. 5 B, C, and F). Likewise, the protein content of
serine473-phosphorylated serine/threonine protein kinase
Akt (Akt) is greater in the L/L mice than in WT, although the
content of total Akt is comparable between the two genotypes
(Fig. 5 D and E).
In contrast to a previous finding that the expression of inducible
NOS and the serum levels of NO2−/NO3− (end products of NO
metabolism) are markedly increased in TGFβ1-null mice (20), we
did not find significant differences between WT and L/L mice in
these parameters (Fig. 5 G and I), although the renal expression
of neuronal NOS was significantly decreased in the L/L mice (Fig.
5H). From these results, we conclude that the NO system is un-
likely to play a causative role in the high blood pressure in the
L/L mice.
Additionally, parameters of the activities of several other sys-
tems related to BP control did not differ in the L/L and WT mice,
includingmetanephrine [WT (n= 6): 47.5± 5.5 pg/mL vs. L/L (n=
6): 38.6 ± 2.9 pg/mL, P = NS] and normetanephrine [WT (n = 6):
668 ± 87 pg/mL vs. L/L (n = 6): 792 ± 89 pg/mL, P = NS], indi-
cators of adrenergic activity, and triiodothyronine [WT (n = 6):
0.97 ± 0.02 pg/mL vs. L/L (n = 6): 0.89 ± 0.07 pg/mL, P =NS] and
thyroxine [WT (n = 6): 3.01 ± 0.13 pg/mL vs. L/L (n = 6): 2.65 ±











































































































Fig. 3. Elevated arterial pressure and decreased heart rate in L/L male mice at age 12 wk. (A) Systolic blood pressure (sBP) in L/L, L/+, WT, H/+, and H/H mice
determined with a tail-cuff method. ‡P < 10−5 vs. WT. (B) Heart rate in the five genotypes of mice with a tail-cuff method. ‡P < 10−5. (C) Systolic blood pressure
(sBP), diastolic blood pressure (dBP), and mean arterial pressure (MAP) studied with telemetry in the five genotypes of mice. ‡P < 10−5 vs. WT. (D) Heart rate in














































































Fig. 4. Renin–angiotensin–aldosterone system in L/L, L/+, WT,
H/+, and H/Hmale mice at age 12 wk. *P < 0.05, **P < 0.01, †P <
0.001, ††P < 10−4 vs. WT. (A) Angiotensin II levels in the
plasma. (B) Active renin concentration in the plasma. (C) Tissue
mRNA levels for the components of renin–angiotensin system.
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Water and Electrolyte Balance in TGFβ1 Hypo/Hypermorphic Mice.
Food intake normalized to body weight did not differ in the five
genotypes (Fig. 6A), but the water intake of the L/L mice was al-
most twice normal (Fig. 6B). In contrast, the urine volume and
osmolarity in the L/Lmice were less than one-fifth normal (Fig. 6C
and G). Their daily excretion of sodium, potassium, and chloride
was similarly reduced (Fig. 6 D–F), although as described above,
their plasma sodium and chloride concentrations and plasma os-
molarity were normal (Tables S1 and S2).
Because of the marked difference between oral intake and
urinary output of water and electrolytes in the L/L mice, we
compared nonurinary routes of output inWT and L/Lmice. Fecal
excretion of electrolytes was not significantly different in the
L/L mice when normalized by body weight (Fig. S4 A–C). How-
ever, electrolytes in the hair were greater in the L/L mice than
WT (Fig. S5) and their metabolic cages tended to show water
condensation, suggesting that they might be losing water in an
attempt to maintain normal body temperature. Evidence favoring
this possibility was our finding that the L/L mice have twice nor-
mal locomotive activity, a 1.1 °C increase in body temperature,
and a heat production that is 1.3 times WT (Fig. S6 A–C).
Thus, the L/L mice are able to maintain near normal plasma
electrolyte levels (except K+) and electrolyte balance despite
their increased water intake and considerable loss of water and
electrolytes via extrarenal mechanisms.
Renal Function in TGFβ1 Hypo/Hypermorphic Mice. Renal histology
in the mice with differences in Tgfb1 expression revealed no
significant differences from WT (Fig. S7). Nor were glomerular
filtration rates and plasma concentrations of urea nitrogen and
creatinine different from WT (Fig. S8 and Tables S1 and S2),
indicating that kidney function in the mice is normal at 12 wk age
when the general effects of different levels of Tgfb1 are already
fully developed.
Renal mRNA levels in the L/L mice of genes related to tu-
bular water and sodium transport were indistinguishable from
WT (Fig. S9). However, in contrast to this absence of differences
in the mRNA expression of the genes that encode the α, β, and γ
subunits of Na+-K+ ATPase (NK; Fig. S9), the activity of NK in
kidney homogenates proved to be markedly increased in the L/L
mice (2.7 times normal in the L/L vs. WT; P < 0.01; Fig. 7A).
This increased NK activity in turn was associated with reduced
phosphorylation of Ser residues of NKα1 in the L/L mice (0.69
times WT; P < 0.05; Fig. 7B), although the amount of NKα1
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Fig. 5. Nitric oxide (NO) system in the kidney of WT and L/L male mice at
age 12 wk. *P < 0.05, †P < 0.001 vs. WT. (A) Ser1177-phosphorylated
endothelial NO synthase (eNOS; %WT). (B) Thr495-phosphorylated eNOS
(%WT). (C) Total eNOS (%WT). (D) Ser473-phosphorylated Akt (%WT). (E )
Total Akt (%WT). (F ) eNOS mRNA levels (%WT). (G) Inducible NOS mRNA
levels (%WT). (H) Neuronal NOS mRNA levels (%WT). (I) Plasma nitrite/ni-































































































































































































Fig. 6. Metabolic study data in L/L, L/+, WT, H/+, and H/H
male mice at age 12 wk. BW, body weight. *P < 0.05 vs. WT,
†P < 0.001 vs. WT. (A) Food consumption. (B) Water con-
sumption. (C) Urine volume. (D) Urinary sodium excretion. (E)

























































































































































































WT  L/L WT  L/L WT  L/L
A B C
Fig. 7. Renal function in TGFβ1 hypomorphic mice. *P < 0.05, **P < 0.01 vs.
WT. †P < 0.05 vs. WT Veh; ††P < 0.05 vs. L/L Veh. (A) Renal activity of Na+-K+
ATPase (NK) studied by ouabain-sensitive conversion of ATP to inorganic
phosphate. (B) Ser phosphorylation of NKα1. (C) Abundance of NKα1 pro-
tein. (D) Total ENaC activity in WT and L/L mice treated with vehicle (Veh),
spironolactone (Spi; 50 mg/kg/d for 7 d), and DOCA (120 mg/kg/d for 3 d). (E)
ENaC open probability (Po). (F) Functional ENaC expression (fN).











Likewise, although the mRNA expression in the L/L mice of
the genes Scnna, Scnnb, and Scnng did not differ from WT, total
epithelial sodium channel (ENaC) activity proved to be markedly
greater (2.0 times WT) in L/L than in WT mice due to increased
ENaC open probability (1.5 times WT) and functional ENaC
expression (1.6 times WT). Systemic elevation of miner-
alocorticoids by deoxycorticosterone acetate (DOCA) injection
increased ENaC activity 1.9-fold in WT but had no further
stimulatory effect in L/L mice, indicating that their ENaC was
near maximally activated (Fig. 7 G–J).
We conclude that, although the amounts of NK and ENaC
proteins and the corresponding mRNAs are not increased in the
L/L mice, tubular sodium reabsorption is increased by super-
normal activation of the proteins.
Pharmacological Normalization of the Hypertension of the Tgfb1 10%
Hypomorphs. Pharmacological tests showed that spironolactone (a
mineralocorticoid receptor antagonist), at levels that did not sig-
nificantly change theBP of theWTmice, decreased theBP and the
plasma volume and increased urinary sodium of the L/L mice to
levels indistinguishable from WT (Fig. 8 A–C, Table S3); it also
decreased total ENaC activity in both L/L and WT mice to ∼35%
of untreated WT and abolished the difference in ENaC activity
between L/L and WT (Fig. 7D). Amiloride (an ENaC inhibitor)
also normalized the BP, plasma volume, and urinary sodium of the
L/L mice (Fig. 8 A–D). In contrast, aliskiren (a renin inhibitor),
losartan (an antagonist for angiotensin II type 1 receptor), when
given at doses that significantly decreased the sBP of WT, did not
normalize the BP of the L/L mice (Fig. 8A). Furosemide (a loop
diuretic) decreased the sBP of the L/L and WT mice indepen-
dently of genotype, while Nω-nitro-L-argininemethyl ester (NAME;
a NOS inhibitor) increased their sBP, likewise independently of
genotype. (Fig. 8A, Table S3).
We conclude that the effects of changes in Tgfb1 expression on
sBP and plasma volume are due to changes in NK and ENaC
activity mediated by the mineralocorticoid receptor and are
correctable by inhibitors of the receptor or of ENaC.
Discussion
The mice generated in the present study have Tgfb1 mRNA ex-
pression graded in five steps from 10% normal in the L/L mice to
300%normal in theH/Hmice. No inflammatory cell infusions were
observed in the tissues of any of our mice. Thus, even 10% normal
expression of Tgfb1 is sufficient to prevent the multifocal in-
flammatory disease that develops in mice unable to synthesize the
protein (9, 10). Plasma levels of active TGFβ1 and renal expression
of p-Smad2 were closely correlated with the expression of Tgfb1,
indicating that the activity of intracellular TGFβ signaling is pro-
portionately modified in our mice. Accordingly, these mice have
allowed us to determine the consequences of genetically de-
termined differences in Tgfb1 expression covering levels that in-
clude those that might be expected to occur in human populations.
The primary finding from our studies of these mice is that both
increases and decreases in Tgfb1 expression cause marked pro-
gressive changes in multiple systems that regulate blood pressure.
The major effects of Tgfb1 expression on blood pressure reg-
ulating systems prove to be mediated by changes in adrenocor-
tical function. Thus, we find, in agreement with previous in vitro
experiments with cultured human adrenocortical cells (21), that
higher than normal levels of TGFβ1 lead to decreases in the
expression of the genes, Cyp11b1 and Cyp11b2, that control the
synthesis of corticosterone and aldosterone, whereas lower than
normal levels of TGFβ1 lead to increased expression of these
genes. We also find, in agreement with previous in vitro experi-
ments with cultured bovine adrenocortical cells (22), that higher
than normal levels of TGFβ1 lead to decreases in the expression
of the genes, Star and Hsd3b1, which control the synthesis of
corticosteroids, whereas lower than normal levels of TGFβ1 lead
to increased expression of these genes. Plasma volumes range
from 50% below normal in the H/H mice to 50% above normal in
the L/L mice. The increased plasma volume of the L/L mice is
accompanied by increased ENaC activity in the kidney and hence
with increased sodium reabsorption. Marked compensatory
changes in the renin–angiotensin system accompany the changes
in plasma volumes, and are sufficient in the H/H, H/+, and L/+
mice to maintain normal systolic blood pressure, even though
plasma volumes and diastolic blood pressure are still abnormal.
The L/L mice, in contrast, develop severe hypertension, despite
having renin levels less than 30% of normal. Their aldosterone/
renin ratios are more than six times normal, and they can rea-
sonably be classified as having secondary hypertension due to
primary aldosteronism comparable to that seen in humans with
idiopathic bilateral adrenal hyperplasia. The hypertension and
aldosteronism of the L/L mice are completely corrected with
subpressor doses of a mineralocorticoid receptor antagonist,
spironolactone, or an ENaC inhibitor, amiloride, or less com-
pletely with a loop diuretic, furosemide. However, their hyper-
tension is not normalized with a renin inhibitor, aliskiren, or an
angiotensin II receptor blocker, losartan, even at doses that de-
crease the blood pressure of WT mice. Thus, the low expression
of Tgfb1 in the hypomorphs leads to primary aldosteronism,
plasma overload, and a form of resistant hypertension.
In humans, hypertension attributable to either an adrenal tumor
or adrenal hyperplasia is one of the more common forms of sec-
ondary hypertension. Resistant hypertension, defined as a failure to
achieve goal blood pressure in a patient who adheres to the maxi-
mum tolerated doses of three antihypertensive drugs of different
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Fig. 8. Pharmacological normalization of the hypertension of the Tgfb1 10% hypomorphs. (A) Systolic blood pressure (sBP) with a tail-cuff method in
12-wk-old WT (white columns) and L/L (black columns) mice administered vehicle (Veh), aliskiren (Ali; 40 mg/kg/d i.p.), losartan (Los; 10 mg/kg/d i.p.),
spironolactone (Spi; 50 mg/kg/d i.p.), amiloride (Ami; 3 mg/kg/d i.p.), furosemide (Fur; 40 mg/kg/d i.p.), or Nω-nitro-L-arginine methyl ester (NAME;
30 mg/kg/d i.p.) for 2 wk. *P < 0.05, **P < 0.01, †P < 0.001, ††P < 10−4 vs. the vehicle-treated group of the same genotype. NS, no significant difference. (B)
Plasma volume in WT and L/L mice without and with spironolactone or amiloride. (C) Urinary sodium excretion. BW, body weight. †P < 0.001 vs. WT.
5604 | www.pnas.org/cgi/doi/10.1073/pnas.1302641110 Kakoki et al.
relatively common and projected to increase (23, 24). Volume ex-
pansion is a frequent pathogenic finding in such patients (23).
Whereas we have not studied the effects of multiple antihyper-
tensive agents on the hypertension of our L/L mice, they are re-
sistant to renin-based drugs probably because their renin–
angiotensin system is maximally down-regulated. They clearly have
abnormal plasma volumes, as do the H/H mice and to a lesser ex-
tent the L/+ and H/+ mice. These findings suggest that decreased
TGFB1 expression should be considered as a possible factor in
patients with resistant hypertension and volume expansion.
In summary, our experiments demonstrate that mice with mod-
est genetically determined increases or decreases in Tgfb1 expres-
sion have significant progressive disturbances in their regulation of
blood pressure and plasma volume. Mice with 10% normal Tgfb1
expression develop primary aldosteronism and markedly impaired
diuresis and natriuresis. Thus, TGFβ1 plays a critical physiological
role in controlling blood pressure and maintaining fluid homeo-
stasis. Similar progressive effects can be expected in humans who
have genetic changes that affect the expression of the TGFB1 gene
or its signaling pathways.
Materials and Methods
We generated TGFβ1 hypomorphic mice by replacing the 3′-UTR of the
Tgfb1 gene with the 3′-UTR of the Fos gene (Fig. 1A). The gene targeting
vector used for this purpose was constructed from the backbone “low-high
vector with insulators” generated by M.K., using the “low-high vector”
generated by H.-S.K., and originally the “OS-dupdel vector” generated by
O.S. The low-high cassette was inserted by homologous recombination into
the Tgfb1 locus of the embryonic stem cell, which is on a C57BL/6 genetic
background. The 5′ short homology arm (1.0 kb) immediately 5′ to the stop
codon was amplified by PCR with primers as follows: Forward 5′-TCATGG-
GACTGTTgctagcC-3′; Reverse 5′-TTTctcgagTTCAGCTGCACTTGCAGGAG-3′
(lowercase indicates restriction sites: NheI and XhoI). The 3′-long homology
arm (4.6 kb) 3′ to the Tgfb1 3′-UTR was excised with HindIII and KpnI from
the BAC clone RP23-421O10 (Invitrogen). The PCR screening of the targeted
ES cell clones was performed with primers as follows (amplicon: 1156 bp):
Forward 5′-GAGTGCTCATGGGACTGTTG-3′ (immediately 5′ to the short
arm); Reverse 5′-TCCTCTCTGTAATGCACCAG-3′ (Fos 3′-UTR). The gene tar-
geting was confirmed by Southern blot using the short arm of the targeting
construct as the probe and genomic DNA (5 μg) digested by NcoI. Geno-
typing of TGFβ1 hypomorphic mice was also performed based on the
presence or absence of the 3′-UTR of Tgfb1 and bGH with real-time
quantitative PCR (ABI 7700 Sequence Detection system; Perkin-Elmer) using
the toe DNA as a template. The primers and probes used for the geno-
typing are shown in Table S4.
The globally TGFβ1 hypermorphic mice (Tgfb1H/+ and Tgfb1H/H mice) were
generated on the C57BL/6 genetic background by obtaining offspring from
the Tgfb1L/+ male mice having a tamoxifen-inducible ubiquitously expressed
Cre recombinase transgene (Jackson Laboratories)-injected tamoxifen
(50 mg·kg−1·d−1 i.p. in sesame oil for 5 d). The effects of spironolactone
(50 mg·kg−1·d−1 i.p. for 4 wk) and amiloride (3 mg·kg−1·d−1 i.p. for 4 wk) in
12-wk-old Tgfb1L/L mice were also studied.
Our experiments were approved by the University of North Carolina In-
stitutional Animal Care and Use Committee.
Other methods are described in SI Materials and Methods.
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